Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 773-780

  Del Rio, Maguy ^a   Molina, Franck ^a   Bascoul Mollevi, Caroline ^a   Copois, Virginie ^a   Bibeau, Frédéric ^a   Chalbos, Patrick ^a   Bareil, Corinne ^a   Kramar, Andrew ^a   Salvetat, Nicolas ^a   Fraslon, Caroline ^a   Conseiller, Emmanuel ^a   Granci, Virginie ^a   Leblanc, Benjamin ^a   Pau, Bernard ^a   Martineau, Pierre ^a   Ychou, Marc ^a  

^a CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IFL PROTOCOL; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ALGORITHM; ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN GENOME; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; TREATMENT RESPONSE; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION; COLORECTAL TUMOR; GENETICS; MIDDLE AGED;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED;

EID: 33947540860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.4187     Document Type: Article

References (43)

1. Weitz J, Koch M, Debus J, et al: Colorectal cancer. Lancet 365:153-165, 2005
2. Vanhoefer U, Harstrick A, Achterrath W, et al: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol 19:1501-1518, 2001
3. Pelley RJ: Oxaliplatin: A new agent for colorectal cancer. Curr Oncol Rep 3:147-155, 2001
4. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
5. Goldberg RM, Sargent DJ, Morton RF, et al: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23-30, 2004
6. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
7. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
8. Iacopetta B, Grieu F, Joseph D, et al: A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85:827-830, 2001
9. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000
10. Kornmann M, Schwabe W, Sander S, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 9:4116-4124, 2003
11. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
12. Paradiso A, Xu J, Mangia A, et al: Topoisomerase-I, thymidylate synthase primary tumor expression and clinical efficacy of 5-FU/ CPT-11 chemotherapy in advanced colorectal cancer patients. Int J Cancer 111:252-258, 2004
13. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298-4304, 2001
14. Adlard JW, Richman SD, Seymour MT, et al: Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol 3:75-82, 2002
15. Ahmed FE: Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn 5:353-575, 2005
16. Mariadason JM, Arango D, Shi Q, et al: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63:8791-8812, 2003
17. Bertucci F, Salas S, Eysteries S, et al: Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 23:1377-1391, 2004
18. Birkenkamp-Demtroder K, Christensen LL, Olesen SH, et al: Gene expression in colorectal cancer. Cancer Res 62:4352-4363, 2002
19. Wang Y, Jatkoe T, Zhang Y, et al: Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 22:1564-1571, 2004
20. Notterman DA, Alon U, Sierk AJ, et al: Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res 61:3124-3130, 2001
21. Eschrich S, Yang I, Bloom G, et al: Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23:3526-3535, 2005
22. Chang JC, Wooten EC, Tsimelzon A, et al: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362:362-369, 2003
23. Iwao-Koizumi K, Matoba R, Ueno N, et al: Prediction of docetaxel response in human breast cancer by gene expression profiling. J Clin Oncol 23:422-431, 2005
24. Jansen MP, Foekens JA, van Staveren IL, et al: Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. J Clin Oncol 23:732-740, 2005
25. Mariadason JM, Arango D, Augenlicht LH: Customizing chemotherapy for colon cancer: The potential of gene expression profiling. Drug Resist Updat 7:209-218, 2004
26. Ghadimi BM, Grade M, Difilippantonio MJ, et al: Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826-1838, 2005
27. Copois V, Bibeau F, Bascoul-Mollevi C, et al: Impact of RNA degradation on gene expression profiles: Assessment of different methods to reliably determine RNA quality. J Biotechnol 127:549-559, 2007
28. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
29. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98:5116-5121, 2001
30. Dodd LE, Pepe MS: Partial AUC estimation and regression. Biometrics 59:614-623, 2003
31. Brown MP, Grundy WN, Lin D, et al: Knowledge-based analysis of microarray gene expression data by using support vector machines. Proc Natl Acad Sci U S A 97:262-267, 2000
32. Michiels S, Koscielny S, Hill C: Prediction of cancer outcome with microarrays: A multiple random validation strategy. Lancet 365:488-492, 2005
33. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004
34. Pepe MS, Longton G, Anderson GL, et al: Selecting differentially expressed genes from microarray experiments. Biometrics 59:133-142, 2003
35. Gatti L, Zunino F: Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 111:127-148, 2005
36. Levy Y, Arbel-Goren R, Hadari YR, et al: Galectin-8 functions as a matricellular modulator of cell adhesion. J Biol Chem 276:31285-31295, 2001
37. Nagy N, Bronckart Y, Camby I, et al: Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 50:392-401, 2002
38. Salahshor S, Goncalves J, Chetty R, et al: Differential gene expression profile reveals deregulation of pregnancy specific beta1 glycoprotein 9 early during colorectal carcinogenesis. BMC Cancer 5:66-80, 2005
39. Bergman BL, Scott RW, Bajpai A, et al: Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc Natl Acad Sci U S A 83:996-1000, 1986
40. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
41. Oike Y, Yasunaga K, Suda T: Angiopoietin-related/ angiopoietin-like proteins regulate angiogenesis. Int J Hematol 80:21-28, 2004
42. Barrier A, Lemoine A, Boelle PY, et al: Colon cancer prognosis prediction by gene expression profiling. Oncogene 24:6155-6164, 2005
43. Barrier A, Boelle PY, Roser F, et al: Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24:4685-4691, 2006